Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (271-280 of 436) with videos related to

Pageof 44
Sort By:
Biophysical Reviews|July 14, 2020
Genetic, clinical, molecular, and pathogenic aspects of the South Asian-specific polymorphic MYBPC3<sup>Δ25bp</sup> variantMohammed Arif, Pooneh Nabavizadeh, Taejeong Song, et al.
Critical Care Medicine|December 24, 2009
Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomesJason N Katz, Bimal R Shah, Elizabeth M Volz, et al.
Journal of the American College of Cardiology|July 9, 2013
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular eventsDeepak Voora, Derek Cyr, Joseph Lucas, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 27, 2019
C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary SyndromesThomas Andersen, Thor Ueland, Tatevik Ghukasyan Lakic, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 25, 2025
Correction to: C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary SyndromesThomas Andersen, Thor Ueland, Tatevik Ghukasyan Lakic, et al.
Circulation|December 18, 2025
Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac DysfunctionWa Du, Madison Ringer, Wei Huang, et al.
Journal of the American Heart Association|December 24, 2022
Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO TrialMarcus Hjort, Kai M Eggers, Tatevik Ghukasyan Lakic, et al.
Journal of Thrombosis and Thrombolysis|May 10, 2012
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trialsDominick J Angiolillo, David J Schneider, Deepak L Bhatt, et al.
Cardiovascular Research|March 4, 2023
Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular diseasePia Davidsson, Susanna Eketjäll, Niclas Eriksson, et al.
European Heart Journal|July 5, 2011
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudyThomas J Povsic, William A Wargin, John H Alexander, et al.
Pageof 44

Showing results (271-280 of 436) with videos related to

Sort By:
Pageof 44
Biophysical Reviews|July 14, 2020
Genetic, clinical, molecular, and pathogenic aspects of the South Asian-specific polymorphic MYBPC3<sup>Δ25bp</sup> variantMohammed Arif, Pooneh Nabavizadeh, Taejeong Song, et al.
Critical Care Medicine|December 24, 2009
Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomesJason N Katz, Bimal R Shah, Elizabeth M Volz, et al.
Journal of the American College of Cardiology|July 9, 2013
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular eventsDeepak Voora, Derek Cyr, Joseph Lucas, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 27, 2019
C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary SyndromesThomas Andersen, Thor Ueland, Tatevik Ghukasyan Lakic, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 25, 2025
Correction to: C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary SyndromesThomas Andersen, Thor Ueland, Tatevik Ghukasyan Lakic, et al.
Circulation|December 18, 2025
Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac DysfunctionWa Du, Madison Ringer, Wei Huang, et al.
Journal of the American Heart Association|December 24, 2022
Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO TrialMarcus Hjort, Kai M Eggers, Tatevik Ghukasyan Lakic, et al.
Journal of Thrombosis and Thrombolysis|May 10, 2012
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trialsDominick J Angiolillo, David J Schneider, Deepak L Bhatt, et al.
Cardiovascular Research|March 4, 2023
Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular diseasePia Davidsson, Susanna Eketjäll, Niclas Eriksson, et al.
European Heart Journal|July 5, 2011
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudyThomas J Povsic, William A Wargin, John H Alexander, et al.
Pageof 44